<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01543464</url>
  </required_header>
  <id_info>
    <org_study_id>MM1120</org_study_id>
    <nct_id>NCT01543464</nct_id>
  </id_info>
  <brief_title>Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients</brief_title>
  <official_title>Combination of IDO/Survivin Peptide Vaccine, GM-CSF, Imiquimod and Temozolomide Chemotherapy for Patients With Metastatic Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inge Marie Svane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Copenhagen University Hospital at Herlev</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess if treatment with IDO/Survivin peptide vaccine can enhance
      the efficacy of temozolomide chemotherapy in patients with metastatic malignant melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondarily to studying the efficacy of the treatment; the investigators examine if treatment
      with IDO/Survivin peptide can induce a measurable cellular T-cell response when the vaccine
      is given in combination with temozolomide treatment for melanoma patients.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Diminished rectruitment
  </why_stopped>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical benefit rate (CBR)</measure>
    <time_frame>18 months</time_frame>
    <description>Primary endpoint is clinical benefit rate defined as complete remission rate + partial response + stable disease for a minimum of 6 months plus assessment of time to progression (TTP).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>Vaccine+adjuvants+temozolomide treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy: Temozolomide</intervention_name>
    <description>Vaccine: 250 microgram IDO5 peptide + 250 microgram Survivin peptide + 500 microL Montanide every 2nd week Adjuvants: 75 microgram GM-CSF + 1 application Imiquimod every 2nd week</description>
    <arm_group_label>Vaccine+adjuvants+temozolomide treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histological verified malignant melanoma

          2. Metastatic disease (brain metastasis allowed if asymptomatic)

          3. Evaluable disease recording to RECIST v. 1.1

          4. Age &gt; 18 years

          5. Performance status, PS=0, PS=1 or PS=2

          6. Life expectancy &gt; 3 months

          7. Adequate bone marrow function

          8. Leucocyte count &gt; 2,5 * 109/L

          9. Granulocyte count &gt; 1,5 * 109/L

         10. Thrombocyte count &gt; 100 * 109/l

         11. Creatinine &lt; 2,5 * UNL 130 micromol/L

         12. Adequate liver function

         13. ASAT &lt; 100 U/L

         14. Bilirubin &lt; 300 U/L

         15. S-hCG negative (fertile women)

         16. Written informed consent

         17. Inclusion at least 4 weeks after major abdominal surgery

         18. If radiotherapy for brain metastases prior to inclusion, then progressive disease
             proven by new brain MR-scan before inclusion

        Exclusion Criteria:

          1. Treatment with immune suppressors (ie. prednisone) not allowed

          2. Other malignancies 3 years prior to inclusion except benign skin lesions

          3. Severe medical condition, severe asthma, severe COL, severe heart- or diabetic disease

          4. Acute/Chronic infection with HIV, hepatitis or tuberculosis

          5. Known severe allergic reactions

          6. Former anaphylactic reactions

          7. Active autoimmune diseases

          8. Pregnant or nourishing women

          9. Psychiatric disease resulting in non-compliance

         10. Known allergic reactions towards Montanide, Imiquimod, Temozolomide or Leukine

         11. Simultaneously treatment with other experimental drugs

        Patients cannot be treated with chemotherapy, radiotherapy (except locally) or
        immunotherapy 14 days within inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Trine Zeeberg Iversen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Cancer ImmuneTherapy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Inge Marie Svane, MD, PhD, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Center for Cancer ImmunoTherapy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Trine Zeeberg Iversen</name>
      <address>
        <city>Brønshøj</city>
        <state>Copenhagen</state>
        <zip>2700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2012</study_first_submitted>
  <study_first_submitted_qc>March 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2012</study_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Inge Marie Svane</investigator_full_name>
    <investigator_title>MD, PhD &amp; Professor</investigator_title>
  </responsible_party>
  <keyword>Indeolamine 2,3 dioxygenase</keyword>
  <keyword>Survivin</keyword>
  <keyword>Montanide</keyword>
  <keyword>Imiquimod</keyword>
  <keyword>GMCSF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Imiquimod</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

